Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10564
Shown on this page
12
Current sort
Recently updated
Location scope
Cincinnati, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cincinnati, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 553–564 of 10,564 matching trials in Cincinnati, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733
View directory record Official record
Conditions
Biliary Atresia
Interventions
Odevixibat
Drug
Lead sponsor
Albireo, an Ipsen Company
Industry
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma (RCC)
Interventions
Pumitamig, Ipilimumab, Cabozantinib, Casdatifan
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Active, not recruiting Phase 3 Interventional

S0820, Adenoma and Second Primary Prevention Trial

NCT01349881
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2032
U.S. locations
989
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032
View directory record Official record
Conditions
High-risk Non-muscle Invasive Bladder Cancer
Interventions
Pembrolizumab, BCG
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Active, not recruiting No phase listed Observational

STOP Persistent AF PAS

NCT05005949
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Arctic Front™ Cardiac Cryoablation Catheter System
Device
Lead sponsor
Medtronic Cardiac Ablation Solutions
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Stamford, Connecticut • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Recruiting Phase 2 Interventional

Advancing Transplantation Outcomes in Children

NCT06055608
View directory record Official record
Conditions
Kidney Transplant
Interventions
Sirolimus, Belatacept, Mycophenolate Mofetil, Tacrolimus (Group1), Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Recruiting Phase 2 Interventional

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968
View directory record Official record
Conditions
Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Interventions
Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Paclitaxel, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
536
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

NCT05035030
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Odevixibat
Drug
Lead sponsor
Albireo, an Ipsen Company
Industry
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
30
States / cities
Lancaster, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Prospective Multi-Center Trial for FemBloc Permanent Birth Control

NCT05977751
View directory record Official record
Conditions
Contraception
Interventions
FemBloc
Device
Lead sponsor
Femasys Inc.
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
12
States / cities
Chandler, Arizona • Palo Alto, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

NCT02286089
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
OpRegen
Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
3
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 12, 2026, 9:46 PM EST